Hospital
Mayo Clinic Health System-Southwest Wisconsin Region, INC.
Mayo Clinic Health System-Southwest Wisconsin Region, INC. was paid $8.41M by Medicaid between Jan 2018 and Dec 2024, across 90 billing codes. Its largest line is 99283, emergency room visit (moderate) — 32% of everything it billed.
33Billing provider infoMAYO CLINIC HEALTH SYSTEM-SOUTHWEST WISCONSIN REGION, INC.
SPARTA, WI 54656
SPARTA, WI 54656
33aNPI1841278637assigned 01/03/2006
33bProvider typeCritical Access Hospital
28Total paid$8.41M
24GClaims103,617
24DCodes billed90
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Wisconsin
Rank by total paid#15 of 48
Median peer was paid$4.30M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BORTNEM, MARK controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,278 | $851K | |
| 2019 | 11,616 | $846K | |
| 2020 | 10,390 | $754K | |
| 2021 | 16,583 | $1.25M | |
| 2022 | 19,998 | $1.56M | |
| 2023 | 18,759 | $1.89M | |
| 2024incomplete | 14,993 | $1.27M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 32% | 11,316 | 9,459 | $2.73M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 6,766 | 5,138 | $1.33M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 5,648 | 4,210 | $1.17M |
| 96361 | Intravenous infusion, hydration; each additional hour | 13% | 1,902 | 1,601 | $1.08M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.7% | 3,508 | 3,134 | $645K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.7% | 870 | 770 | $312K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 765 | 685 | $242K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.3% | 3,466 | 1,489 | $109K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 192 | 150 | $60K |
| 80053 | Comprehensive metabolic panel | <1% | 5,890 | 5,097 | $55K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,790 | 1,631 | $52K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,113 | 1,025 | $50K |
78 more codes
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,448 | $47K |
| 87631 | <1% | 436 | $45K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 8,380 | $45K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,223 | $42K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,236 | $41K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,857 | $40K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 280 | $36K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 436 | $26K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,187 | $25K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 398 | $23K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 57 | $20K |
| 84484 | <1% | 1,804 | $17K | |
| 80061 | Lipid panel | <1% | 1,073 | $13K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 510 | $12K |
| 81025 | <1% | 1,452 | $11K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,758 | $10K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,151 | $8K |
| 81001 | <1% | 3,057 | $8K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,496 | $7K |
| 83690 | <1% | 1,409 | $7K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 138 | $6K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 372 | $6K |
| 80306 | <1% | 451 | $6K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 219 | $6K |
| 97162 | <1% | 159 | $6K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 12 | $6K |
| 83880 | <1% | 290 | $5K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 16 | $5K |
| 85610 | <1% | 1,536 | $5K | |
| 83605 | <1% | 676 | $5K | |
| 82077 | <1% | 258 | $5K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 299 | $5K |
| 85379 | <1% | 621 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 698 | $4K |
| 81003 | <1% | 1,522 | $3K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 37 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,889 | $3K |
| 83735 | <1% | 621 | $3K | |
| 73630 | <1% | 115 | $2K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 78 | $2K |
| 86140 | <1% | 416 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 12 | $1K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,062 | $1K |
| 82947 | <1% | 393 | $1K | |
| 73610 | <1% | 68 | $1K | |
| 85027 | <1% | 223 | $952.02 | |
| 82570 | <1% | 162 | $744.18 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,085 | $690.96 |
| 84702 | <1% | 48 | $668.04 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,572 | $647.76 |
| 82043 | <1% | 111 | $598.28 | |
| 82248 | <1% | 203 | $587.50 | |
| 80050 | General health panel | <1% | 20 | $402.75 |
| 87103 | <1% | 25 | $364.13 | |
| 97161 | <1% | 14 | $354.83 | |
| 87040 | <1% | 49 | $284.34 | |
| 80143 | <1% | 26 | $258.27 | |
| 82948 | <1% | 62 | $228.70 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,799 | $166.49 |
| 80179 | <1% | 14 | $135.99 | |
| 87077 | <1% | 13 | $78.66 | |
| 87186 | <1% | 13 | $74.76 | |
| 86850 | <1% | 14 | $62.86 | |
| 73110 | <1% | 12 | $53.47 | |
| 86900 | <1% | 12 | $37.42 | |
| 86901 | <1% | 12 | $37.42 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 638 | $27.79 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 551 | $26.86 |
| 0764T | <1% | 28 | $17.62 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 19 | $10.93 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 248 | $6.86 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 111 | $6.33 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 34 | $4.42 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 41 | $0.00 |
| A9270 | Non-covered item or service | 0% | 507 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 14 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 91 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBORTNEM, MARK (CHIEF FINANCIAL OFFICER)
Parent organizationMAYO CLINIC HEALTH SYSTEM-SOUTHWEST WISCONSIN REGION, INC.
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.